Logo image of MED.DE

MEDICLIN AG (MED.DE) Stock Fundamental Analysis

FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR

2.88  -0.02 (-0.69%)

Fundamental Rating

3

Overall MED gets a fundamental rating of 3 out of 10. We evaluated MED against 23 industry peers in the Health Care Providers & Services industry. MED may be in some trouble as it scores bad on both profitability and health. MED is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year MED has reported negative net income.
In the past year MED had a positive cash flow from operations.
In multiple years MED reported negative net income over the last 5 years.
Each year in the past 5 years MED had a positive operating cash flow.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

1.2 Ratios

MED has a Return On Assets of -1.23%. This is amonst the worse of the industry: MED underperforms 88.46% of its industry peers.
The Return On Equity of MED (-5.26%) is worse than 88.46% of its industry peers.
With a Return On Invested Capital value of 1.74%, MED is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
MED had an Average Return On Invested Capital over the past 3 years of 1.64%. This is below the industry average of 5.35%.
The last Return On Invested Capital (1.74%) for MED is above the 3 year average (1.64%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.23%
ROE -5.26%
ROIC 1.74%
ROA(3y)-0.01%
ROA(5y)0.01%
ROE(3y)-0.06%
ROE(5y)-0.04%
ROIC(3y)1.64%
ROIC(5y)1.41%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5

1.3 Margins

With a Operating Margin value of 2.31%, MED is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
MED's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 83.19%, MED belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 2.31%
PM (TTM) N/A
GM 83.19%
OM growth 3Y377.27%
OM growth 5Y1.2%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y0.08%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MED is destroying value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
Compared to 5 years ago, MED has about the same amount of shares outstanding.
Compared to 1 year ago, MED has an improved debt to assets ratio.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.47, we must say that MED is in the distress zone and has some risk of bankruptcy.
MED's Altman-Z score of 1.47 is in line compared to the rest of the industry. MED outperforms 57.69% of its industry peers.
The Debt to FCF ratio of MED is 10.45, which is on the high side as it means it would take MED, 10.45 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 10.45, MED is not doing good in the industry: 61.54% of the companies in the same industry are doing better.
A Debt/Equity ratio of 2.00 is on the high side and indicates that MED has dependencies on debt financing.
MED's Debt to Equity ratio of 2.00 is on the low side compared to the rest of the industry. MED is outperformed by 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 10.45
Altman-Z 1.47
ROIC/WACC0.41
WACC4.21%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

MED has a Current Ratio of 1.74. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a Current ratio of 1.74. This is amongst the best in the industry. MED outperforms 84.62% of its industry peers.
MED has a Quick Ratio of 1.70. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.70, MED belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.7
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -154.78%.
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 2.04%.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 3.20% on average per year.
EPS 1Y (TTM)-154.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.14%
Revenue 1Y (TTM)2.04%
Revenue growth 3Y4.55%
Revenue growth 5Y3.2%
Sales Q2Q%0.96%

3.2 Future

MED is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 77.58% yearly.
The Revenue is expected to grow by 1.77% on average over the next years.
EPS Next Y352%
EPS Next 2Y126.27%
EPS Next 3Y77.58%
EPS Next 5YN/A
Revenue Next Year0.09%
Revenue Next 2Y1.54%
Revenue Next 3Y1.77%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 0.4

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

MED reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 7.31, the valuation of MED can be described as very cheap.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
MED's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 7.31
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 92.31% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a rather cheap valuation: MED is cheaper than 84.62% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3
EV/EBITDA 3.5
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MED's earnings are expected to grow with 77.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y126.27%
EPS Next 3Y77.58%

More info and screens

0

5. Dividend

5.1 Amount

MED does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICLIN AG

FRA:MED (3/6/2025, 7:00:00 PM)

2.88

-0.02 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2024-11-04
Earnings (Next)04-30 2025-04-30
Inst Owners2.09%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap136.80M
Analysts83.33
Price Target4.36 (51.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)14.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.31
P/S 0.18
P/FCF 3
P/OCF 1.55
P/B 0.64
P/tB 0.72
EV/EBITDA 3.5
EPS(TTM)-0.23
EYN/A
EPS(NY)0.39
Fwd EY13.68%
FCF(TTM)0.96
FCFY33.38%
OCF(TTM)1.86
OCFY64.71%
SpS16.23
BVpS4.47
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.23%
ROE -5.26%
ROCE 2.47%
ROIC 1.74%
ROICexc 2.38%
ROICexgc 2.48%
OM 2.31%
PM (TTM) N/A
GM 83.19%
FCFM 5.92%
ROA(3y)-0.01%
ROA(5y)0.01%
ROE(3y)-0.06%
ROE(5y)-0.04%
ROIC(3y)1.64%
ROIC(5y)1.41%
ROICexc(3y)2.1%
ROICexc(5y)1.71%
ROICexgc(3y)2.27%
ROICexgc(5y)1.85%
ROCE(3y)2.33%
ROCE(5y)2%
ROICexcg growth 3Y411.76%
ROICexcg growth 5Y-8.69%
ROICexc growth 3Y421.46%
ROICexc growth 5Y-5.86%
OM growth 3Y377.27%
OM growth 5Y1.2%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity 2
Debt/FCF 10.45
Debt/EBITDA 4.16
Cap/Depr 50.86%
Cap/Sales 5.56%
Interest Coverage 0.78
Cash Conversion 86.71%
Profit Quality N/A
Current Ratio 1.74
Quick Ratio 1.7
Altman-Z 1.47
F-Score6
WACC4.21%
ROIC/WACC0.41
Cap/Depr(3y)34.41%
Cap/Depr(5y)39.93%
Cap/Sales(3y)3.66%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-154.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.14%
EPS Next Y352%
EPS Next 2Y126.27%
EPS Next 3Y77.58%
EPS Next 5YN/A
Revenue 1Y (TTM)2.04%
Revenue growth 3Y4.55%
Revenue growth 5Y3.2%
Sales Q2Q%0.96%
Revenue Next Year0.09%
Revenue Next 2Y1.54%
Revenue Next 3Y1.77%
Revenue Next 5YN/A
EBIT growth 1Y-54.13%
EBIT growth 3Y398.97%
EBIT growth 5Y4.45%
EBIT Next Year591.97%
EBIT Next 3Y95.67%
EBIT Next 5YN/A
FCF growth 1Y29.19%
FCF growth 3Y-24.12%
FCF growth 5YN/A
OCF growth 1Y54.52%
OCF growth 3Y-12.96%
OCF growth 5Y22.78%